Quince Therapeutics

115 articles with Quince Therapeutics

• Quince Therapeutics Confirms Receipt of Unsolicited Acquisition Offer from Echo Lake Capital

  3/22/2023

  Quince Therapeutics, Inc., a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients’ lives, confirmed that it received an unsolicited offer to acquire the company from Echo Lake Capital.

• Quince Therapeutics Provides Pipeline Update and Business Outlook for 2023

  1/30/2023

  Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients’ lives, today provided an update on the company’s development pipeline and business outlook for 2023.

• Quince Therapeutics Completes the Sale of Legacy Protease Inhibitor Portfolio to Lighthouse Pharmaceuticals

  1/27/2023

  Quince Therapeutics, Inc. (Nasdaq: QNCX) announced the sale of the company’s legacy small molecule protease inhibitor portfolio, including COR588, COR388, COR852, and COR803, pursuant to an asset purchase agreement with Lighthouse Pharmaceuticals, Inc., an entity co-founded by Casey Lynch, former chief executive officer of Quince’s predecessor company Cortexyme.

• Quince Therapeutics Presents Preclinical Data at MHSRS 2022 Demonstrating Preclinical Efficacy of Bone-targeting Platform for Traumatic Bone Injury

  9/16/2022

  Quince Therapeutics, Inc. today detailed highlights from the company’s participation at the Military Health System Research Symposium (MHSRS 2022), which took place September 12 to September 15, 2022, in Kissimmee, Florida.

• Quince Therapeutics Presents Preclinical Data at ASBMR 2022 Demonstrating Application of Bone-targeting Platform for Spinal Fusion and Bone Cancer Indications

  9/12/2022

  Quince Therapeutics Presents Preclinical Data at ASBMR 2022 Demonstrating Application of Bone-targeting Platform for Spinal Fusion and Bone Cancer Indications.

• Quince Therapeutics Presents Preclinical Data at OI 2022 Demonstrating Potential of a Targeted Anabolic for Accelerated Bone Healing of Osteogenesis Imperfecta Fractures

  8/30/2022

  Quince Therapeutics, Inc. (Nasdaq: QNCX), today presented preclinical data at the 14th International Conference on Osteogenesis Imperfecta (OI 2022) demonstrating the potential of its novel targeted therapeutic NOV004 to treat fracture in osteogenesis imperfecta (OI) by promoting accelerated increases in bone density, strength, and healing directly at the site of bone fracture.

• Quince Therapeutics to Present at Upcoming Scientific Meetings

  8/25/2022

  Quince Therapeutics, Inc. (Nasdaq: QNCX), announced that the company will present at a number of scientific meetings taking place in September 2022, including the 14th International Conference on Osteogenesis Imperfecta (OI 2022), The American Society for Bone and Mineral Research Annual Meeting (ASBMR 2022), and the Military Health System Research Symposium (MHSRS 2022).

• Quince Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference on August 11, 2022

  8/4/2022

  Quince Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference on August 11, 2022.

• Quince Therapeutics Details Strategic Growth Plan with Launch of New Corporate Name

  8/1/2022

  Quince Therapeutics, Inc. (Nasdaq: QNCX), a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases, provided an overview of its strategic growth plan in conjunction with its corporate name change today.

• Cortexyme Announces Preclinical Data Demonstrating Efficacy of COR803 for the Treatment of Coronavirus Infections

  6/21/2022

  Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on advancing therapeutics for rare and degenerative diseases, today announced new preclinical data demonstrating the efficacy of the company’s 3CLpro inhibitor, COR803, for treatment of coronavirus infections, including COVID-19 disease, caused by SARS-CoV-2 infection.

• Cortexyme Appoints June Bray to its Board of Directors

  6/13/2022

  Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on rare and degenerative diseases, today announced the appointment of June Bray, a pharmaceutical industry veteran and global drug development and regulatory process expert, to the company’s Board of Directors.

• Cortexyme Successfully Completes Acquisition of Novosteo

  5/20/2022

  Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company developing therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today announced the completion of its acquisition of Novosteo, a privately-held biotech company focused on targeted therapeutics to treat rare skeletal diseases, bone cancer and injury.

• Cortexyme Appoints Dr. Philip Low to Its Board of Directors

  5/20/2022

  Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today announced the appointment of Dr. Philip S. Low, a renowned targeted drug discovery researcher and veteran biotech entrepreneur, to the company’s Board of Directors.

• Cortexyme to Participate at 4th International Conference on Porphyromonas gingivalis and Related Species in Oral and Systemic Diseases

  5/12/2022

  Cortexyme to Participate at 4th International Conference on Porphyromonas gingivalis and Related Species in Oral and Systemic Diseases.

• Cortexyme Announces Agreement to Acquire Novosteo

  5/10/2022

  Cortexyme, Inc. today announced that it entered into an agreement under which the company plans to acquire Novosteo, a privately-held biotech company focused on targeted therapeutics to treat rare skeletal diseases, bone cancer and injury.

• 

  Cortexyme Charts New Course with Acquisition of Rare Disease Player

  5/10/2022

  Cortexyme has entered into a deal to acquire Novosteo. Once the deal is finalized, the companies will enter the rare disease space and operate under the name Quince Therapeutics.
• 

  Clinical Catch-Up: Moderna COVID-19 Vaccine for Kids and Much More

  3/28/2022

  Although it was relatively quiet in COVID-19-related clinical trials, there was plenty of other clinical trial news. Here’s a look.

• Cortexyme Provides New GAIN Trial Data at AD/PD 2022 Demonstrating Potential Benefit of Lysine Gingipain Inhibition in Mild to Moderate Alzheimer’s Population

  3/21/2022

  Cortexyme, Inc. presented new target engagement and biomarker data from the GAIN Trial at the AD/PD™ 2022 International Conference on Alzheimer’s and Parkinson’s Diseases.

• 

  Cortexyme, SQZ, Others Present New Insights into Alzheimer's and Parkinson's

  3/21/2022

  The 2022 International Conference on Alzheimer’s and Parkinson’s Disease ended last weekend, but it reported on numerous research studies and insights into the diseases.

• Cortexyme Appoints Marwan Sabbagh, MD, to its Board of Directors

  3/15/2022

  Cortexyme, Inc. today announced the appointment of Marwan Noel Sabbagh, MD, FAAN, a board-certified neurologist and leading expert in Alzheimer’s and dementia care, to the company’s Board of Directors.